With Global Horizon, Chinese Angle strategy, BOCG strives to support true innovation and disruptive technology of life science.
Accumulated 100+ years’ experience and US$ 1+ billion proven record, the BOCG veteran team builds its office and franchise in Shenzhen, Shanghai, Hong Kong, and Gothenburg of Sweden, and extensive networks and footprint in Greater China, Asia, USA and Europe.
A signatory to the UN PRI and committed to promoting sustainable development and impact investment.
On September 11, 2024, the Hong Kong International Biotechnology Convention (BIOHK2024) was grandly opened. Frank Yang, Founding Partner & CEO of BOCG, was honored to join distinguished experts from the fields of investment, entrepreneurship, and medicine for a panel discussion on the theme, “Can Biotech Be Hong Kong’s Next Pillar of Growth?”
On September 10th, the 2024 Shenzhen Biomedical Industry Investment and Promotion Conference was successfully held. BOCG’s portfolio companies, Boan Biotech and Ribo Life Science, participated in the signing ceremony as partners, announcing their intent to establish a presence in Shenzhen. Frank Yang, Founding Partner and CEO of BOCG, was interviewed by several media outlets, sharing his insights on Shenzhen’s unique advantages and prospects for developing the biomedical industry as an innovative city in the Greater Bay Area.
Recently, BOCG's portfolio company, Innorna, announces that China National Medical Products Administration (NMPA) has granted a Drug Clinical Trial Approval Notice for its self-developed Herpes Zoster (HZ) mRNA vaccine IN001; meanwhile, U.S. FDA orphan drug designation granted to IN022 for the Treatment of Homocystinuria after it was granted rare pediatric disease designatio.
